OPKO Health, Inc. Earnings Recaps
Q3 2025
Oct 30, 2025
OPKO Health's Q3 2025 results showcased strategic progress, highlighted by the successful sale of its oncology division and a focus on core clinical operations, driving a commitment to shareholder value.
Key takeaways
- Completed the sale of BioReference Health's oncology division for $192.5 million plus an additional $32.5 million in performance-based earn-out.
- Achieved a 5.3% increase in testing volume at BioReference, with a 20% rise in adoption of the 4Kscore test for prostate cancer.
- Repurchased $25.1 million in stock during 2025 to enhance shareholder returns, with $126 million remaining under the repurchase program.
- Advanced pipeline with four therapeutics in clinical development, including promising candidates in the immuno-oncology space and a COVID-19 antibody initiative.
- Focused on operational efficiencies and growth through new customer segments and revenue streams, maintaining a streamlined workforce at BioReference.